HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice.

Abstract
Nine cases of newborn patients who developed hyperbilirubinemia due to blood group incompatibility and were treated with high dose (1 gram/Kg) intravenous immunoglobulin (IVIG) are described. In 7 of the 9 patients the rise of bilirubin level was attenuated and exchange transfusion was not required following treatment with IVIG. Of the two patients who did require an exchange transfusion despite IVIG treatment, one had the exchange performed immediately following the IVIG infusion, allowing no time for observation of the therapy effect. Our results suggest that IVIG administration may be efficacious in the treatment of immune hemolytic hyperbilirubinemia of the newborn but further studies are required to validate the efficacy of this treatment.
AuthorsZ Ergaz, I Arad
JournalJournal of perinatal medicine (J Perinat Med) Vol. 21 Issue 3 Pg. 183-7 ( 1993) ISSN: 0300-5577 [Print] Germany
PMID8229608 (Publication Type: Journal Article)
Chemical References
  • Immunoglobulins, Intravenous
  • Bilirubin
Topics
  • Bilirubin (blood)
  • Erythroblastosis, Fetal (blood, therapy)
  • Exchange Transfusion, Whole Blood
  • Female
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Immunotherapy
  • Infant, Newborn
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: